Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Iopromide
Drug ID BADD_D01182
Description Iopromide is a low osmolar, non-ionic X-ray contrast agent for intravascular administration. It functions as a contrast agent by opacifying blood vessels in the path of flow of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs. Available as the FDA-approved product Ultravist, iopromide is used in radiographic studies such as intra-arterial digital subtraction angiography (IA-DSA), cerebral and peripheral arteriography, peripheral venography, excretory urography, brain computer tomography (CT), coronary arteriography, left ventriculography, visceral angiography, and aortography.
Indications and Usage Iopromide, as the product Iovist, is indicated for use as an X-ray contrast agent in the following procedures: Intra-arterial digital subtraction angiography (IA-DSA) (150 mg I/mL) Cerebral arteriography and peripheral arteriography (300 mg I/mL) Coronary arteriography and left ventriculography, visceral angiography and aortography (370 mg I/mL) Peripheral venography (240 mg I/mL) Excretory urography (300 mg I/mL) Contrast computed tomography (CT) imaging of head and body (300 mg I/mL and 370 mg I/mL)
Marketing Status approved
ATC Code V08AB05
DrugBank ID DB09156
KEGG ID D01893
MeSH ID C038192
PubChem ID 3736
TTD Drug ID D07GNP
NDC Product Code 50419-344; 50419-346; 50419-347; 50419-348
UNII 712BAC33MZ
Synonyms iopromide | lopromid | N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-(2-methoxyacetamido)-N-methylisophthalamide | iopromid | Ultravist 300 | Clarograf | Ultravist
Chemical Information
Molecular Formula C18H24I3N3O8
CAS Registry Number 73334-07-3
SMILES CN(CC(CO)O)C(=O)C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)NC(=O)COC)I
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lacrimal structural disorder06.06.04.013---
Language disorder17.02.08.015; 19.19.01.0060.014227%-
Vascular malformation03.07.03.004; 24.03.03.014---
Mouth swelling07.05.04.007; 10.01.05.020; 23.04.01.0200.010670%-
Noninfective sialoadenitis07.06.04.0030.007113%-
Multiple organ dysfunction syndrome08.01.03.0570.039124%
Anal incontinence07.01.06.029; 17.05.01.0210.035567%
Apallic syndrome17.02.04.0180.007113%-
Ruptured cerebral aneurysm17.08.01.059; 24.02.04.0050.007113%-
Slow response to stimuli17.02.05.0630.010670%-
Laryngeal discomfort22.12.03.0090.010670%-
Pharyngeal hypoaesthesia17.02.06.034; 22.04.05.0170.010670%-
Binocular eye movement disorder06.05.02.017; 17.02.05.0520.007113%-
Communication disorder19.19.01.0080.007113%-
Foaming at mouth07.05.05.019; 08.01.03.070; 17.02.05.0560.028454%-
Asthmatic crisis22.03.01.018---
Oral mucosal erythema07.05.05.0230.007113%-
Tongue pruritus07.14.02.0210.038412%-
Lip pruritus07.05.05.0210.043392%-
Spinal pain08.01.08.030; 15.02.01.008; 17.10.01.0200.007113%-
Eyelid thickening06.06.04.021; 23.07.05.0070.007113%-
Vein rupture12.01.11.011; 24.03.02.0320.014227%-
Hemianaesthesia17.02.06.0430.014227%-
Administration site extravasation08.02.04.019; 12.07.04.0190.019206%-
Contrast media allergy10.01.01.010; 12.02.05.0160.138711%-
Mucosal disorder08.01.06.029---
Pharyngeal swelling22.04.05.0280.022763%-
Swelling of eyelid06.04.04.018; 10.01.05.026; 23.04.01.0260.014227%-
Type II hypersensitivity10.01.03.0640.007113%-
The 15th Page    First    Pre   15    Total 15 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene